<DOC>
	<DOCNO>NCT02436759</DOCNO>
	<brief_summary>This Phase 3 study evaluate safety efficacy RVL-1201 Ophthalmic Solution treatment acquire blepharoptosis ( ptosis ) ass safety comfort RVL-1201 Ophthalmic Solution extend dose period 6 week .</brief_summary>
	<brief_title>Study Safety Efficacy RVL-1201 Treatment Acquired Blepharoptosis</brief_title>
	<detailed_description>Ptosis experience approximately 12 % adult age 50 . It unilateral bilateral abnormal droop upper eyelid usually occur partial complete dysfunction muscle ( ) elevate upper eyelid : levator palpebrae superioris and/or Müller 's muscle . Treatment acquire ptosis usually involve surgery , risk infection , bleeding , undercorrection , reduce vision , lagophthalmos ( inability close eyelid completely ) mechanical treatment e.g scleral contact lenses bar lift eyelid , eyelid ptosis crutch attach glass , adhesive tape putty affix upper eyelid supraorbital structure . RVL-201 ophthalmic solution develop provide reversible pharmacologic option patient acquire ptosis candidate surgery wish undergo surgery . The objective study evaluate safety efficacy RVL-1201 ophthalmic solution treatment acquire blepharoptosis ass safety comfort RVL-1201 ophthalmic solution extend dosing period 6 week . Subjects randomize ( 2:1 ) one 2 treatment arm treat 42 day : - RVL-1201 0.1 % one full drop eye QD morning ( N = 100 ) - RVL-1201 vehicle ( placebo ) 1 full drop per eye QD morning ( N = 50 ) Efficacy assess LPFT , validate visual field test use HVF Analyzer photographic measurement MRD ( distance pupillary light reflex central margin upper lid ) PFD ( distance upper lid margin lower lid margin central visual axis ) . Safety assessment include bilateral SLE/CFS , measurement PD external photograph , dilate ophthalmoscopy/fundus examination , tonometry , Snellen VA use recent correction , vital sign ( BP/HR ) , collection adverse event ( AEs ) .</detailed_description>
	<mesh_term>Blepharoptosis</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male female subject 18 year age old . 2 . Presence follow Screening : . Loss reliable LPFT ≥ 8 point top 2 row ( LPFT Eligibility Score ) ; subject must see least 9 total point top 4 row ( LPFT Total Score ) . . This criterion must meet Visit 1 Hour 0 ( V1H0 ) Visit 1 Hour 6 ( V1H6 ) LPFT assessment ii . There must ≤ 4 point variance V1H0 V1H6 LPFT Eligibility Score ; ; AND b . The MRD , distance central pupillary light reflex central margin upper lid , must ≤ 2 mm ( visible central pupillary light reflex default 0 ) eye Inclusion Criterion # 2a AND c. Snellen visual acuity ( VA ) 20/80 good eye Inclusion Criteria # 2a # 2b . 3 . Presence follow Baseline : . Loss reliable LPFT ≥ 8 point top 2 row ( LPFT Eligibility Score ) eye Inclusion Criterion # 2a ; subject must see least 9 total point top 4 row ( LPFT Total Score ) . . This criterion must meet Visit 2 Hour 0 ( V2H0 ) LPFT assessment . ii . There must ≤ 4 point variance V1H6 V2H0 LPFT Eligibility Score ; AND b . Marginal Reflex Distance ( MRD ) , distance central pupillary light reflex central margin upper lid , must ≤ 2 mm ( visible central pupillary light reflex default 0 ) eye Inclusion Criterion # 2a ; AND c. Snellen VA 20/80 good eye Inclusion Criteria # 2a # 2b . 4 . Female subject must 1 year postmenopausal , surgically sterilize , woman childbearing potential negative urine pregnancy test Visit 1 . Women childbearing potential must use acceptable form contraception throughout study . Acceptable method include use least one following : intrauterine ( intrauterine device ) , hormonal ( oral , injection , patch , implant , ring ) , barrier spermicide ( condom , diaphragm ) , abstinence . 5 . Able selfadminister study medication study medication administer caregiver throughout study period . 6 . Subjects must able understand sign IRB approve informed consent form prior participation studyrelated procedure . In either eye 1 . Congenital ptosis . 2 . Presence either following : 1 . Pseudoptosis ( upper eyelid dermatochalasis overhang upper eyelid margin ) 2 . Dermatochalasis extend less 3 mm upper eyelid margin . 3 . Horner syndrome . 4 . Marcus Gunn jaw wink syndrome . 5 . Myasthenia gravis . 6 . Mechanical ptosis , include ptosis due orbital lid tumor , cicatricial process affect movement upper lid , enophthalmos . 7 . Previous ptosis surgery ( previous blepharoplasty [ ] allow provide surgery take place &gt; 3 month prior Visit 1 ) . 8 . Lid position affect lid conjunctival scar . 9 . Visual field loss cause ptosis . 10 . History herpes keratitis . 11 . History closed/narrow angle glaucoma ( unless patent peripheral iridotomy perform &gt; 3 month prior Visit 1 ) . 12 . Periocular neurotoxin ( eg , Botox , Xeomin , Dysport , Myobloc ) injection within 3 month prior Visit 1 study . 13 . Topical application bimatoprost ( ie , Latisse® ) eyelashes within 7 day prior Visit 1 study . 14 . Use topical ophthalmic medication ( include antiallergy [ eg , antihistamine ] , dry eye [ ie , Restasis® ] antiinflammatory drug [ include nonsteroidal antiinflammatory drug ( NSAIDs ) steroid ] assign study medication within 7 day prior Visit 1 study . Topical ophthalmic prostaglandin analogue treatment elevate intraocular pressure permit dosed evening accordance approve prescribing information . All topical antiglaucoma medication prohibit 15 . Intravitreal injection ( eg , Lucentis® , Eylea® , Avastin® , Triesence® ) within 7 day prior Visit 1 study . 16 . Current punctal plug placement punctal plug study . 17 . Use counter ( OTC ) vasoconstrictor/decongestant eye medication ( eg , Visine® L.R.® ) ophthalmic nonophthalmic α adrenergic agonist include OTC product ( eg , Afrin® ) time study ; nonpreserved artificial tear allow . General 18 . Resting heart rate ( HR ) outside normal range ( 60100 beat per minute ) . 19 . Hypertension rest diastolic blood pressure ( BP ) &gt; 105 mm Hg . 20 . Use monoamine oxidase inhibitor ( MAOIs ; eg , isocarboxazid , phenelzine , tranylcypromine ) within 14 day prior Visit 1 study . 21 . Advanced arteriosclerotic disease history cerebrovascular accident ( CVA ) . 22 . History hyperthyroidism thyroid eye disease ( ie , exophthalmos , upper eyelid retraction , diplopia secondary extraocular muscle involvement ) . Hypothyroidism control medication allow . 23 . Patients diabetic retinopathy may enrol . However , patient insulin dependent diabetes , diabetes require oral hypoglycemic drug , diet control diabetes allow . 24 . Pregnancy lactation . 25 . Diagnosed benign prostatic hypertrophy require medicinal therapy ; previous prostatectomy allow . 26 . History contact systemic allergic reaction oxymetazoline sympathomimetic drug ( eg , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine , fepradinol , methoxamine ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>